Mutual funds holding Glaxosmithkline Pharmaceuticals shares
74 mutual fund schemes held Glaxosmithkline Pharmaceuticals shares in their latest portfolios (October 2026, or September 2026 where a fund house's October 2026 portfolio is not yet in), worth about ₹2,163 cr in all. The largest holders by value are Kotak Large & Mid Cap Fund (1.0% of the fund), SBI Midcap Fund (1.3% of the fund), Nippon India Pharma Fund (2.8% of the fund).
Against the month before, 0 schemes added Glaxosmithkline Pharmaceuticals as a new holding and 5 sold out of it completely.
Sold out: Motilal Oswal BSE 1000 Index Fund, HDFC BSE 500 Index Fund, Motilal Oswal Nifty 500 Index Fund, SBI Nifty 500 Index Fund, DSP Nifty 500 Index Fund
By category: Index Fund (31), Sectoral/Thematic (15), Mid Cap (6), Multi Cap (4), Large & Mid Cap (3), Flexi Cap (3).
4 actively managed schemes holding it are rated A+ or A on their track record, among them Bajaj Finserv Flexi Cap Fund, Mahindra Manulife Small Cap Fund, Quant ELSS Tax Saver Fund, Aditya Birla Sun Life Multi-Cap Fund.
Every scheme holding Glaxosmithkline Pharmaceuticals, by value
And 34 more schemes with smaller holdings.
Value: the scheme's assets under management × the stock's weight, approximate. Change: the weight against the previous month's portfolio, in percentage points; it moves with the share price as well as with buying and selling. Links go to each scheme's Regular plan.
Common questions
How many mutual funds hold Glaxosmithkline Pharmaceuticals shares?
74 schemes held Glaxosmithkline Pharmaceuticals in their latest monthly portfolios (October 2026, or September 2026 where a fund house's October 2026 portfolio is not yet in), worth about ₹2,163 cr in all.
Which mutual fund holds the most Glaxosmithkline Pharmaceuticals shares?
By value, Kotak Large & Mid Cap Fund: about ₹302 cr, 1.00% of the fund.
Where does this data come from?
From the monthly portfolios that every fund house must publish by the 10th of the following month. Values are approximate: the fund's assets under management multiplied by the stock's weight in the portfolio.
This page lists which funds hold a stock. It is not a view on the stock or a recommendation to buy or sell it or any fund. Ratings describe past track records, not a forecast.
Send us your CAS and get a written report: which of your funds to keep, which to exit and when, where new SIPs should go, and what each change costs in tax.